NanoViricides (NYSE:NNVC) Now Covered by started coverage on shares of NanoViricides (NYSE:NNVCGet Rating) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Shares of NNVC opened at $1.49 on Friday. NanoViricides has a 1 year low of $1.42 and a 1 year high of $7.86. The firm’s 50 day moving average is $1.91. The stock has a market cap of $17.18 million, a price-to-earnings ratio of -1.94 and a beta of 1.05.

NanoViricides (NYSE:NNVCGet Rating) last announced its quarterly earnings data on Monday, February 14th. The company reported ($0.17) earnings per share (EPS) for the quarter.

NanoViricides Company Profile (Get Rating)

NanoViricides, Inc, a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide.

Featured Stories

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with's FREE daily email newsletter.